Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.
暂无分享,去创建一个
Hong Wu | Gad Getz | Wanling Xie | Stephen P Finn | Ingo K Mellinghoff | Igor Vivanco | Massimo Loda | G. Getz | M. Loda | Todd Golub | I. Mellinghoff | C. Sawyers | I. Vivanco | Hong Wu | J. Jiao | C. Tran | N. Kennedy | W. Xie | S. Finn | Nicolaos J Palaskas | Charles L Sawyers | Roger J Davis | Todd Golub | Nicolaos Palaskas | Joshua Rose | Chris Tran | Jing Jiao | Norman J Kennedy | Joshua Rose | R. Davis | N. Palaskas | Nicolaos J. Palaskas
[1] T. Golub,et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.
[2] E. Lander,et al. Reactive oxygen species have a causal role in multiple forms of insulin resistance , 2006, Nature.
[3] K. Inoki,et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.
[4] J. J. Chen,et al. Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. , 2000, American journal of respiratory cell and molecular biology.
[5] Richard A. Flavell,et al. The Bax Subfamily of Bcl2-Related Proteins Is Essential for Apoptotic Signal Transduction by c-Jun NH2-Terminal Kinase , 2002, Molecular and Cellular Biology.
[6] F. Collins,et al. Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Bruce,et al. Somatic mutations of PTEN in glioblastoma multiforme. , 1997, Cancer research.
[8] Michael E. Greenberg,et al. Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.
[9] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[10] F. Khuri,et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.
[11] J. Olefsky,et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. , 2000, Molecular endocrinology.
[12] M. Yaniv,et al. Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras , 1994, Cell.
[13] D. Accili,et al. Tyrosine Phosphorylation of Insulin Receptor Substrate-1 in Vivo Depends upon the Presence of Its Pleckstrin Homology Region (*) , 1995, The Journal of Biological Chemistry.
[14] Huajun Yan,et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade , 2005, Molecular Cancer Therapeutics.
[15] C. Lyle,et al. Inhibition of Cell Proliferation and Cell Cycle Progression by Specific Inhibition of Basal JNK Activity , 2004, Journal of Biological Chemistry.
[16] Daniel J. Freeman,et al. PTEN Deletion Leads to Up-regulation of a Secreted Growth Factor Pleiotrophin* , 2006, Journal of Biological Chemistry.
[17] M. White,et al. c-Jun N-terminal Kinase (JNK) Mediates Feedback Inhibition of the Insulin Signaling Cascade* , 2003, The Journal of Biological Chemistry.
[18] A. Klippel,et al. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways , 1996, Molecular and cellular biology.
[19] S. Morrison,et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.
[20] Y. Gotoh,et al. Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes. , 2003, Molecular endocrinology.
[21] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[22] M. Wigler,et al. Design of a retroviral-mediated ecdysone-inducible system and its application to the expression profiling of the PTEN tumor suppressor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[23] Chaohong Sun,et al. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. , 2006, Journal of medicinal chemistry.
[24] R. Mamillapalli,et al. Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases , 2000, Current Biology.
[25] F. Christians,et al. PTEN Expression Causes Feedback Upregulation of Insulin Receptor Substrate 2 , 2001, Molecular and Cellular Biology.
[26] C. Rondinone,et al. Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. , 2001, Diabetes.
[27] B. Foster,et al. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.
[28] A. Manning,et al. Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.
[29] S. Lowe,et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.
[30] A. Kral,et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors , 2022 .
[31] Hong Wu,et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[32] W. Hahn,et al. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. , 2003, Cancer cell.
[33] T. Hambuch,et al. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Schlessinger,et al. Activation of the JNK pathway is essential for transformation by the Met oncogene , 1997, The EMBO journal.
[35] M E Greenberg,et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. , 1997, Science.
[36] K. Petersen,et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. , 2004, The New England journal of medicine.
[37] T. Golub,et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.
[38] R. Davis,et al. Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.
[39] M. Kracht,et al. Inducible Expression of a Constitutively Active Mutant of Mitogen-activated Protein Kinase Kinase 7 Specifically Activates c-JUN NH2-terminal Protein Kinase, Alters Expression of at Least Nine Genes, and Inhibits Cell Proliferation* , 2002, The Journal of Biological Chemistry.
[40] Todd R. Golub,et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[41] A. Coulson,et al. A functional genomic analysis of cell morphology using RNA interference , 2003, Journal of biology.
[42] D. Geschwind,et al. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[43] R. Flavell,et al. JunD mediates survival signaling by the JNK signal transduction pathway. , 2003, Molecular cell.
[44] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[45] P. Houghton,et al. IRS-1: auditing the effectiveness of mTOR inhibitors. , 2006, Cancer cell.
[46] Zhijian Zhao,et al. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[47] Mehdi Tnani,et al. Elevated JNK activation contributes to the pathogenesis of human brain tumors , 2002, Oncogene.
[48] J. Blenis,et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[49] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[50] P. Nelson,et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.
[51] Y. Le Marchand-Brustel,et al. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. , 2005, Biochimie.
[52] Michael Karin,et al. A central role for JNK in obesity and insulin resistance , 2002, Nature.
[53] P. Pandolfi,et al. Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.
[54] M. Berger,et al. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. , 2001, Cancer research.
[55] Peter Angel,et al. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1 , 1988, Cell.
[56] Richard A. Flavell,et al. Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts , 2002, Nature Genetics.
[57] D. Pfaff,et al. Inhibition of neuronal phenotype by PTEN in PC12 cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[58] Hong Wu,et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. , 2003, Cancer cell.
[59] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[60] S. Sciacchitano,et al. Different subcellular localization and phosphoinositides binding of insulin receptor substrate protein pleckstrin homology domains. , 2000, Molecular endocrinology.
[61] A. Satterthwaite,et al. Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. , 1995, Immunity.